Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding SBIO?
Track your performance easily
SBIO Price & Analysis
SBIO ETF Chart & Stats
Day’s Range― - ―
52-Week Range$24.96 - $33.82
Previous Close$25.65
VolumeN/A
Average Volume (3M)7.42K
AUM85.86M
NAV25.62
Expense Ratio0.50%
Holdings Count104
Beta0.95
Inception DateDec 31, 2014
Last Dividend Ex-Date
Dec 19, 2019Dividend YieldN/A
Shares Outstanding3,550,000
Standard Deviation0.08
10 Day Avg. Volume14,038
30 Day Avg. Volume7,423
Alpha-0.00940
SBIO ETF News
SBIO ETF FAQ
What was SBIO’s price range in the past 12 months?
SBIO lowest ETF price was $24.96 and its highest was $33.82 in the past 12 months.
What is the AUM of SBIO?
As of Oct 17, 2023 The AUM of SBIO is 85.86M.
Is SBIO overvalued?
According to Wall Street analysts SBIO’s price is currently Undervalued.
Does SBIO pay dividends?
SBIO pays a Annually dividend of $0.01 which represents an annual dividend yield of N/A. See more information on SBIO dividends here
How many shares outstanding does SBIO have?
SBIO has 3,550,000 shares outstanding.
Which hedge fund is a major shareholder of SBIO?
Currently, no hedge funds are holding shares in SBIO
SBIO ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Immunovant, Inc.
4.17%
Alkermes plc
3.93%
Vaxcyte, Inc.
3.73%
ACADIA Pharmaceuticals Inc.
3.27%
Insmed
3.16%
Cerevel Therapeutics Holdings Inc
3.06%
Krystal Biotech, Inc.
2.76%
Axsome Therapeutics Inc.
2.66%
Amicus Therapeutics
2.64%
Corcept Therapeutics
2.48%
Total31.86%
ETF Description
ALPS Medical Breakthroughs ETF
SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.